GH - Guardant Health - Stock Price & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US40131M1099
Blood Tests, Tissue Tests, Data Analytics, Software Solutions
Guardant Health Inc, a pioneer in precision oncology, offers a comprehensive range of blood and tissue tests, data sets, and analytics to healthcare professionals and researchers globally. These innovative solutions enable the early detection and monitoring of cancer, as well as the identification of potential treatment options.
The company's flagship product, Guardant360, is a liquid biopsy test that analyzes circulating tumor DNA (ctDNA) in blood samples to detect cancer mutations. This non-invasive test provides valuable insights for clinicians to make informed treatment decisions. Additionally, Guardant Health offers a suite of tests, including Guardant360 LDT, Guardant360 CDx Test, and Guardant360 Response Test, which cater to specific cancer types and treatment stages.
Guardant Health's portfolio also includes GuardantINFINITY, a test designed for advanced cancer patients, and GuardantOMNI, which provides comprehensive genomic profiling for cancer research. Furthermore, the company offers GuardantConnect, an integrated software solution that connects patients with clinical trials and relevant treatment options.
In addition to its testing solutions, Guardant Health provides a range of development services, including companion diagnostic development, clinical study setup, and technology licensing. These services enable biopharmaceutical companies to accelerate their cancer research and drug development programs.
The company has also developed cutting-edge digital platforms, such as Guardant Galaxy, an AI-backed digital pathology platform that enhances cancer biomarker detection. Moreover, Guardant Health has collaborated with Illumina, Inc. to advance cancer research through the sharing of specimen samples.
Headquartered in Palo Alto, California, Guardant Health was founded in 2011 with a mission to transform cancer care through innovative genomics and data analytics. With its commitment to improving patient outcomes, the company continues to push the boundaries of precision oncology.
For more information, please visit Guardant Health's website at https://guardanthealth.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
GH Stock Overview
Market Cap in USD | 2,523m |
Sector | Healthcare |
Industry | Diagnostics & Research |
GiC SubIndustry | Health Care Services |
TER | 0.00% |
IPO / Inception | 2018-10-04 |
GH Stock Ratings
Growth 5y | -71.8 |
Fundamental | -53.2 |
Dividend | |
Rel. Performance vs Sector | -4.35 |
Analysts | 4.59/5 |
Fair Price Momentum | 21.23 USD |
Fair Price DCF | - |
GH Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
GH Growth Ratios
Growth Correlation 3m | -96.1% |
Growth Correlation 12m | 13.6% |
Growth Correlation 5y | -81.4% |
CAGR 5y | -20.39% |
CAGR/Mean DD 5y | -0.39 |
Sharpe Ratio 12m | 0.04 |
Alpha vs SP500 12m | -62.00 |
Beta vs SP500 5y weekly | 1.22 |
ValueRay RSI | 58.69 |
Volatility GJR Garch 1y | 57.33% |
Price / SMA 50 | -6.21% |
Price / SMA 200 | -7.58% |
Current Volume | 1854.8k |
Average Volume 20d | 1404.6k |
External Links for GH Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of October 29, 2024, the stock is trading at USD 22.20 with a total of 1,854,805 shares traded.
Over the past week, the price has changed by +6.53%, over one month by -2.97%, over three months by -37.07% and over the past year by -14.22%.
According to ValueRays Forecast Model, GH Guardant Health will be worth about 23.1 in October 2025. The stock is currently trading at 22.20. This means that the stock has a potential upside of +4.23%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 40.3 | 81.4 |
Analysts Target Price | 53 | 139 |
ValueRay Target Price | 23.1 | 4.23 |